Glenmark Pharma to present updated info on GBR 830 at International Investigative Dermatology Meeting

GBR 830 is a first-in-class, investigational, anti-OX40 monoclonal antibody for treatment of moderate-to-severe atopic dermatitis

Glenmark Pharma has announced that new and updated data on GBR 830 will be presented at the upcoming International Investigative Dermatology Meeting (IID) in Orlando, Florida. The IID meeting occurs only once every five years and brings together top researchers from across the globe to further the understanding of skin biology and dermatologic disease. The GBR 830 presentations at IID 2018 include one oral presentation and three poster presentations on GBR 830, an investigational treatment for moderate-to severe atopic dermatitis.

“In the five years since the last IID meeting, our lead dermatology asset, GBR 830, has progressed from an early preclinical asset to one that is now in Phase 2b clinical efficacy trials. The advancement of GBR 830 marks a major milestone for our company, and is evidence of our rapid transformation into an organisation on the leading-edge of innovative research,” said Fred Grossman, President and Chief Medical Officer, Glenmark Pharmaceuticals.